[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ömer Faruk Okumuş\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100616932","halp-score-blood-based-inflammatory-indices-and-salivary-mmp-8-in-periodontal-disease-and-healing-after-non-surgical-therapy-100616932",false,"NCT07312045","HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy","The Relationship of HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 Levels With Periodontal Disease and Healing After Non-Surgical Periodontal Therapy","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Ability to provide informed consent\n* No systemic diseases or conditions affecting periodontal status\n* For Healthy Group: Probing depth ≤3 mm, no attachment loss, no radiographic bone loss\n* For Gingivitis Group: Gingival inflammation and bleeding on probing without attachment loss or bone loss\n* For Periodontitis Group: Stage III or stage IV periodontitis according to 2018 classification\n* No periodontal treatment within the past 6 months\n* Willingness to attend follow-up visits\n\nExclusion Criteria:\n\n* Systemic diseases influencing periodontal inflammation (e.g., diabetes, autoimmune disorders)\n* Current pregnancy or lactation\n* Use of antibiotics, anti-inflammatory medications, or immunosuppressive drugs within the last 3 months\n* Smokers or individuals using tobacco products\n* History of periodontal surgery in the last 6 months\n* Presence of fewer than 20 natural teeth\n* Any condition that may interfere with study participation or data reliability",true,"ALL","18 Years","65 Years",{"count":21,"type":22},180,"ESTIMATED","OBSERVATIONAL","This observational clinical study aims to investigate the relationship between the HALP score (Hemoglobin × Albumin × Lymphocyte \u002F Platelet), several blood-based inflammatory indices (including NLR, PLR, LMR, and SII), and salivary MMP-8 levels in individuals with periodontal health, gingivitis, and stage III\u002FIV periodontitis. The study also evaluates how these biomarkers relate to healing following non-surgical periodontal therapy.\n\nA total of 180 participants aged 18-65 years will be included: 50 healthy individuals, 50 patients with gingivitis, and 80 patients with stage III\u002FIV periodontitis. All participants will undergo periodontal clinical examination and provide blood and saliva samples at baseline. Individuals in the gingivitis and periodontitis groups will receive standard non-surgical periodontal treatment (full-mouth debridement) and will return for a 3-month follow-up visit, where periodontal measurements will be repeated. In the periodontitis group, an additional blood sample will be collected at the 3-month follow-up visit.\n\nThe primary objective is to determine whether baseline HALP score, systemic inflammatory indices, and salivary MMP-8 levels differ between participants who show good versus poor healing after treatment. Secondary objective include comparing biomarker levels across periodontal status groups. The findings may contribute to early prediction of treatment response and personalized periodontal care.",[26,27,28],"Periodontal Diseases","Periodontitis","Gingivitis; Chronic","RECRUITING","2025-12-16",{"date":32,"type":33},"2025-12-31","ACTUAL",{"date":35,"type":33},"2025-11-25",{"date":37,"type":22},"2026-11-25",{"name":39,"class":40},"Ömer Faruk Okumuş","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":41},"100613132","salivary-mitofusin-1-levels-in-periodontitis-associations-with-disease-severity-smoking-and-treatment-response-100613132","NCT07262606","Salivary Mitofusin-1 Levels in Periodontitis: Associations With Disease Severity, Smoking, and Treatment Response","Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Systemically healthy (no history of diabetes mellitus, immunodeficiency, malignancy, or other systemic conditions that could affect periodontal status).\n* Have a minimum of 20 natural teeth (excluding third molars).\n* No antibiotic therapy or periodontal treatment in the last 6 months.\n\nFor Healthy Control Group:\n\nNo clinical attachment loss. Probing depth ≤ 3 mm. No radiographic evidence of bone loss. Low gingival and plaque index scores.\n\nFor Mild Periodontitis Group:\n\nDiagnosed with Stage I or II periodontitis according to the 2018 AAP\u002FEFP classification.\n\nClinical attachment loss of 1-4 mm. Radiographic bone loss of ≤15-33%. Non-smoker.\n\nFor Severe Periodontitis Group:\n\nDiagnosed with Stage III or IV periodontitis according to the 2018 AAP\u002FEFP classification.\n\nClinical attachment loss ≥ 5 mm. Radiographic bone loss to the mid-advanced level of the root. Non-smoker.\n\nFor Severe Periodontitis with Smoking Group:\n\nMeets all criteria for the Severe Periodontitis Group. Regular smoker (at least 10 cigarettes per day for a minimum of 5 years).\n\nExclusion Criteria:\n\n* Fewer than 20 natural teeth (excluding third molars).\n* Presence of any systemic disease (e.g., diabetes mellitus, immunological disorders, cancer).\n* Use of antibiotics or receiving periodontal treatment in the last 6 months.\n* Pregnancy or lactation.\n* For non-periodontitis groups (Healthy Control): Any signs of periodontitis.\n* For periodontitis groups (all): History of smoking cessation for at least 5 years (must be either a current regular smoker or a never-smoker, depending on the group definition).",{"count":49,"type":22},104,"INTERVENTIONAL",[52],"NA","Periodontitis (gum inflammation) is a common disease worldwide. This study aims to investigate a novel biomarker, a protein called Mitofusin-1 (Mfn1), in saliva that may be associated with the severity of periodontitis and response to treatment. The study will include periodontally healthy individuals, individuals with mild to severe periodontitis, and smokers with severe periodontitis. Participants will receive saliva samples and undergo clinical periodontal examinations. Individuals with periodontitis will receive standard periodontal treatment, and changes in Mfn1 levels will be assessed 3 months after treatment. The study is expected to shed light on the potential utility of Mfn1 as a marker in the diagnosis and follow-up of periodontitis.",[55,56],"Periodontal Disease","Chronic Periodontitis (Disorder)",[58,59,60,61,62],"Mitofusin-1","Saliva","Biomarker","Periodontal Treatment","Smoking","2025-12-01",{"date":65,"type":33},"2025-12-03",{"date":67,"type":33},"2025-11-01",{"date":69,"type":22},"2026-11-01",{"name":39,"class":40},""]